RX Biosyent Inc

BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) today released a summary of its
financial results for the third quarter 2008. Sales decreased by 8.9% from
$1,050,013 in first nine months of 2007 to $956,414 in first nine months of
2008. The company incurred a loss of ($118,363) in the first nine months of 2008
compared to a gain of $31,410 in first nine months of 2007. This loss is
predominantly due to the higher pharmaceutical operating expenses for the
establishment of the hospital division and the launch of Ciprofloxacin
Injection, which was first shipped in May 2008.


Total working capital has increased by 5.5% from $918,615 on June 30, 2008 to
$969,168 on September 30, 2008. Cash and cash equivalents have also increased as
a percentage to total working capital from 74% in June 2008 to 77% in September
2008.


Full details of 2008 quarter three results and Financial Statements and
Management's Discussion & Analysis have been posted on sedar.com.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada.
These pharmaceuticals will compete in both the branded and generic market
segments and will not require further product development investment other than
regulatory costs.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024